NCT02132299View on ClinicalTrials.gov

Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

August 31, 2015

Conditions
MalariaPlasmodium Falciparum Malaria
Interventions
BIOLOGICAL

PfSPZ Vaccine

Aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites (PfSPZ)

BIOLOGICAL

Normal Saline (Placebo)

BIOLOGICAL

PfSPZ Challenge

Live, infectious, aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites (PfSPZ) for CHMI

Trial Locations (1)

Unknown

Bagamoyo Research and Training Center, Ifakara Health Institute, Kingani Estate, PO Box 74, Bagamoyo

All Listed Sponsors
collaborator

Ifakara Health Institute

OTHER

collaborator

Swiss Tropical & Public Health Institute

OTHER

collaborator

Tanzania Commission for Science and Technology

OTHER

lead

Sanaria Inc.

INDUSTRY

NCT02132299 - Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults | Biotech Hunter | Biotech Hunter